Moderna's Melanoma Win and Veteran Data Land Alongside a Raised Outlook and a Norovirus Setback
Published on 11/12/2026 at 07:02 | Editorial boerse-global.de
Moderna will step up to the plate at the Jefferies Global Health Care Conference on 18 November 2026 at 11:00 GMT, a booking that lands just days after the company's analyst day on 12 November 2026 — a date Moderna itself flagged in its SEC-filed earnings release. The two appearances give management back-to-back platforms to frame a story that has grown considerably more layered in recent weeks.
The strongest card is in oncology. Moderna and Merck reported positive Phase 3 results for the combination of intismeran plus pembrolizumab in patients whose melanoma had been surgically removed. According to the companies, the pairing cut the risk of recurrence or death by 42% versus pembrolizumab alone — a comparison that measures the added benefit of intismeran on top of the existing drug, not a comparison against untreated patients.
Not every readout went Moderna's way. The company disclosed on 6 November that its Phase 3 norovirus vaccine study failed to clear the criteria for early success at the interim analysis. Moderna will not enrol the additional cohort planned for this season, a decision that covers both the interim finding and the intended expansion of the trial population.
Veteran Study Puts mNEXSPIKE Ahead of Comirnaty
Separately, Moderna announced publication in JAMA Network Open of a comparative study of mNEXSPIKE against Comirnaty. Among US veterans aged 65 and older, mNEXSPIKE showed a relative vaccine effectiveness of 35.9% against medically treated COVID-19 illness. Against COVID-19-related hospitalisations, the relative effectiveness came in at 47.0%.
Should investors sell immediately? Or is it worth buying Moderna?
The observational, real-world analysis covered roughly 294,000 participants matched on comparable characteristics. Moderna was explicit about the limits of the design, noting that residual confounding could have influenced the results. The published figures therefore describe an observed association between the vaccine used and the disease outcomes studied — not a proven causal effect.
Canada Clears Two Respiratory Shots
Regulators approved mFLUSIVA, a seasonal influenza vaccine, and mCOFLU, a combined influenza and COVID-19 shot, both for adults aged 50 and over. Moderna said it will work with Canadian health authorities and immunisation partners on future availability.
On the numbers front, Moderna posted third-quarter 2026 revenue of $1.3 billion, up 29% year on year, and a net profit of $162 million. Cash, cash equivalents and investments are now expected to reach $8.1 billion to $8.3 billion by year-end. Full-year 2026 revenue growth is guided to 15% to 25%, a sharp upgrade from the up-to-10% previously held out — though those full-year figures remain company expectations.
At least one analyst house likes the shape of the quarter. Overweight was maintained, with the firm citing third-quarter product sales, the lifted revenue growth outlook and the liquidity position as its reasons.
Ad
Moderna Stock: New Analysis - 12 November
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
